Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i4.20
pages 311-337

Cyclodextrin Derivatives in Pharmaceutics

E. Albers
Department of Pharmaceutics and Biopharmaceutics, Christian Albrecht University, Gutenbergstr. 76, D-24118 Kiel, Germany
B. W. Muller
Department of Pharmaceutics and Biopharmaceutics, Christian Albrecht University, Gutenbergstr. 76, D-24118 Kiel, Germany

ABSTRAKT

The current cyclodextrin (CD) literature is reviewed concerning synthesis, characterization, and pharmaceutical relevant applications of CD derivatives. Although natural CDs have been used extensively to improve pharmaceutical properties, the effects of chemically modified CDs on the solubility, dissolution rate, and stability of drugs are overproportional. Concerning the parenteral application, the major interest is focussed on highly water-soluble, randomly substituted hydroxyalkyl derivatives of β- and γ-CD such as 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD). Although the heptakis-(2,6-di-O-methyl)-β-cyclodextrin is applied in the pharmaceutical field, 2-HP-β-CD is predestined as a parenteral drug carrier owing to its weak hemolytic activity and intrinsically amorphous character. A minimal average degree of substitution is especially preferred when 2-HP-β-CD is used as solubilizer of pharmaceuticals for the use in parenteral applications. The influence of the type, degree, and pattern of substitution of the CDs, as well as substituent effects of the guest molecule is elucidated.


Articles with similar content:

Broad-Spectrum Anti-Cancer Activity of O2-Arylated Diazeniumdiolates
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 3
Larry K. Keefer
PART IV. Cytokine and Hormone Immunotherapy
Treatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity

Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Kathleen M. Wyvill, Seth M. Steinberg, Giovanna Tosato, Andrew T. Catanzaro, Richard F. Little, James M. Pluda, Isaac R. Rodriguez-Chavez, Robert Yarchoan, Karen Aleman
Colloidosomes: An Emerging Vesicular System in Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 4
Yashwant Gupta, Satish Shilpi, Anekant Jain, Sanjay Kumar Jain
Current Trends in Self-Emulsifying Drug Delivery Systems (SEDDSs) to Enhance the Bioavailability of Poorly Water-Soluble Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 1
Rohit Karwal, Tanmay S. Markandeywar, Goutam Rath, Tarun Garg
Cyclodextrins—Enabling Excipients: Their Present and Future Use in Pharmaceuticals
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.14, 1997, issue 1
Diane O. Thompson